Selected Publications of Saeed Qureshi

1. Qureshi SA. **Limitations of Some Commonly Described Practices in Drug Dissolution Testing and Suggestions to Address These.** *Am. Pharmaceutical Reviews. 2011: (Jan/Feb), 44-49*.

2. Qureshi, SA. **Determining blood concentration-time (C-t) profiles from in vitro dissolution results and product evaluation – carbamazepine.** *http://www.drug-dissolution-testing.com/?p=601*

3. Qureshi, SA. **Reporting and Analyzing Drug Dissolution Results – A Systematic Approach**. *Am. Pharmaceutical Reviews*. 2010: (May/June), 11-15.

4. Qureshi, SA. ***In Vitro-In Vivo* Correlation (IVIVC) and Determining Drug Concentrations in Blood from Dissolution Testing – A Simple and Practical Approach.** *The Open Drug Delivery Journal*, 2010: *4*, 38-47.

5. Qureshi SA. **A Crescent-shaped Spindle for Improved Dissolution Testing**. *Pharmeuropa Bio & Scientific Notes*. 2009:1, 55-66.

6. Qureshi SA. **Drug Dissolution Testing: Selecting a Dissolution Medium**. *Am. Pharmaceutical Reviews*. 2009:1, 2-5.

7. Qureshi SA. **A simple and economical approach/concept to evaluate quality of pharmaceutical products based on an improved dissolution testing methodology**. *The Open Drug Delivery Journal*. 2;2008:33-37 (http://www.bentham.org/open/toddj/)

8. Qureshi SA. **Performance verification of drug dissolution apparatuses – controversy, its causes and a suggested solution.** *Am. Pharmaceutical Reviews*. 2008:11, 11-15.

9. Qureshi SA. **Development and validation of drug dissolution methods – a rational and systematic approach**. *Am. Pharmaceutical Reviews*. 2007: 10(3), 41-45.

10. Qureshi SA. **Comparative impact of stirring and shearing in drug dissolution testing with USP Paddle and Crescent-shaped spindles.** *Dissolution Technologies.* 2006: 13(1), 25-30.

11. Qureshi SA. **Developing discriminatory drug dissolution tests and profiles: some thoughts for consideration on the concept and its interpretation.** *Dissolution Technologies.* 2006: 13(4), 18-23.

12. Qureshi SA. **The challenges of dissolution testing today: two perspectives.** *Tablets and Capsules*, 2006: 4(5), 28-36.

13. Qureshi SA. **(Invited) Response to a letter to the Editor on an article "A New Crescent-shaped Spindle For Drug Dissolution Testing - But Why a New Spindle?** *Dissolution Technologies.* 2005:12, 26-32.

14. Qureshi SA. **Biopharmaceutical principles for drug products development and assessment: Bioavailability, bioequivalence and dissolution evaluation of solid oral products"** *Pharmaceutical Canada*. June 2005:29-34.

15. Qureshi SA. **Drug dissolution testing- deficiencies and some suggestions for improvement**. *Am. Pharmaceutical Reviews*. 2005:8, 52-55.

16. Qureshi SA. **Improved drug dissolution and product characterization using the crescent-shaped spindle.** *J. Pharm. Pharmacol.* 2004:56, 1135-1141.

17. Qureshi SA. **Choice of rotation speed (rpm) for bio-relevant drug dissolution testing using a Crescent-shape spindle.** *Eur. J. Pharm. Sci*. 2004:23, 271-275.

18. Qureshi SA. **A new crescent-shaped spindle for drug dissolution testing - but why a new spindle?** *Dissolution Technologies.* 2004:11(4), 3-18.

19. Qureshi SA and Shabnam J. **Applications of a new device (spindle) for improved characterization of drug release (dissolution) of pharmaceutical products.** *Eur. J. Pharm. Sci.*, 2003: 19, 291-297.

20. Qureshi SA and Shabnam J. **Cause of high variability in drug dissolution and its impact on setting tolerances**. *Eur. J. Pharm. Sci.* 2001:12, 271-276.

21. Qureshi SA. **Drug dissolution testing - the technique, its role and limitations"** *Pharmaceutical Canada*. Spring 2001, 25-29.

22. Qureshi SA and McGilveray IJ. **"Typical" variability in drug dissolution testing: study with USP and FDA calibrator tablets and a marketed drug (glibenclamide) product**. *Eur. J. Pharm. Sci*. 1999: 7, 249-258.

23. Qureshi SA and McGilveray IJ. **Assessment of pharmaceutical quality of furosemide tablets from multinational markets**. *Drug Devel. Ind. Pharm*. 1998: 24(11), 995-1005.

24. Boivert J, Caillé G, McGilveray IJ and Qureshi SA. **Quantification of ketoprofen enantiomers in human plasma based on solid-**

phase extraction and enantioselective column chromatography. *J. Chromatogr. B.* 1997:690, 189-193.

25. Qureshi SA. **Calibration - The USP dissolution apparatus suitability test.** *Drug Inf J*. 1996: 30, 1055-1061.

26. McGilveray IJ and Qureshi SA. **Role of *in vitro* dissolution test -overview and recent progress of risk-assessment procedure**. Bio International '96 Proceedings, Eds. K. Midha and T. Nagai, FIP Bio International '96 Proceedings, Business Center for Academic Societies Japan (BCASJ), pp. 253-258 (1996).

27. **FIP Guidelines for Dissolution Testing of Solid Oral Products**, Published in *Pharmacopeial Forum*, **21** (1995) 1371-1382, and Pharm. Ind. **57** (1995) 362-369. The guidelines are developed by the contributions from 18 scientists, representing different countries, including two from Canada (Qureshi, S.A, & McGilveray, I.J.).

28. Qureshi SA and McGilveray IJ. **A critical assessment of the USP dissolution apparatus suitability test criteria**. *Drug Develop Ind Pharm.* 1995: 21(8), 905-924.

29. Blume H, Qureshi SA, Ali SL and McGilveray IJ. **Evaluation of pharmaceutical quality of prednisone tablets from multinational markets**. *Drug Develop and Ind Pharm*. 1995: 21(8), 925-942.

30. Qureshi SA, Caillé G, Lacasse Y (*the late*) and McGilveray IJ. Pharmacokinetics of Two Enteric-Coated Ketoprofen Products in Humans with Or Without Co-Administration of Omeprazole". *Pharm. Res*. 1994: 11, 1669-72.

31. Qureshi SA and McGilveray IJ. **Impact of different deaeration methods on the USP dissolution apparatus suitability test criteria**. *Pharmacopeial Forum*. 1994: 20, 8565-8566.

32. Qureshi SA, Caillé G, Brien R, Piccirilli, G, Yu V and McGilveray IJ. **Application of a flow-through dissolution method for the evaluation of oral formulations of nifedipine**. *Drug Develop Ind Pharm*. 1994: 20(11), 1869-1882.

33. Qureshi SA, Laganière S, Caillé G, Gossard D, Lacasse Y, and McGilveray, IJ. **Effect of an acute dose of alcohol on the pharmacokinetics of oral nifedipine in humans** *Pharm. Res.* 1992: 6, 683-686.

34. Qureshi SA and McGilveray IJ. **Dissolution studies of selegiline tablets** *Pharmacopeial Forum* 1991: 17, 1973-1976.

35. Gallicano KD, McGilveray IJ, Qureshi SA, Nitchuk W, Chakraborty B, Boyd C. **Situation paper: comparative bioavailability of oral contraceptive products**". *Clin. Biochem*. 1991: 24, 107-111.

36. Qureshi SA, Laganieré S, McGilveray IJ, Lacasse Y and Caillé G. **Nifedipine-alcohol interaction**. *JAMA* 1990: 264, 1660-1661.

37. Qureshi SA and Huang H. **Determination of B_6 vitamers in serum by simple isocratic high performance liquid chromatography**. *J Liquid Chromatography*. 13;1990:191-201.

38. Qureshi SA and Buttar HS. **A comparative study of the pharmacokinetics of propranolol and its major metabolites in the rat after oral and vaginal administration**. *Xenobiotica*. 1990: 19, 883-890.

39. Qureshi SA and Buttar HS. **High performance liquid chromatographic determination of propranolol and its metabolites in rat serum**. *J. Chromatogr*. 1988: 431, 465-470.